98412 20211216131138.0 sideral 122174 ART-2019-122174 eng Ascaso, F. Universidad de Zaragoza (orcid)0000-0001-9876-5850 Association between mitochondrial haplogroups and ranibizumab response in neovascular age-related macular degeneration 2019 Access copy available to the general public Unrestricted Purpose : The association between mitochondrial DNA (mtDNA) haplogroup and the risk of neovascular age-related macular degeneration (nAMD) has been reported. This prospective, observational clinical study analyzes the anatomical and functional outcomes after one year of intravitreal ranibizumab therapy in nAMD patients according to the mt-DNA haplogroup. Methods : Ninety-eight eyes corresponding to 91 patients with nAMD were treated with three consecutive monthly intravitreal ranibizumab 0.5 mg followed by a flexible pro re nata (PRN). Retreatment criteria were: loss =5 ETDRS letters; increased central foveal thickness (CFT) >100 µm; intra or subretinal fluid on OCT; new or persistent macular haemorrhages. Exclusion criteria were previous treatment with photodynamic therapy or anti-VEGF drug; vitrectomy or any other retinal disease; corneal or lens opacities. Patients were classified into four groups according to their mtDNA haplogroup determined by PCR (Hg H- m.7028C>T; Hg HV- m.14766T>C; Hg JT- m.421 6T>C and Hg U- m.12308A>G). Chi-square, Kolmogorov-Smirnov, ANOVA, Mann-Whitney, Kruskal-Wallis, analysis of variance, Wilcoxon, and Friedman tests were used. SPSS 21.0 program. A p value < 0.05 was statistically significant. Results : Gender, age, risk factors (smoking, diabetes, arterial hypertension and dyslipidemia) and neovascular lesion type were equally distributed among four groups. There were no significant differences between groups in baseline or after loading fase in best corrected visual acuity (BCVA) or CFT. At 4 months, BCVA was significantly higher than baseline in haplogroups HV (p = 0.02), JT (p = 0.002) and U (p = 0.002). CFT was significantly lower in all haplogroups (HV, p<0.001;JT, p=0.028;U, p=0.043;Others, p=0.007). Eighteen patients were excluded at 12 months because of exclusion criteria, however baseline variables were equally distributed among four groups. At 12 months, BCVA in HV and U did not show significant worsening; however, JT showed lower BCVA values than baseline. CFT values in JT were higher than baseline (p = 1.00), whereas HV and U were significantly lower than baseline (HV, p < 0.001; U, p = 0.007). CFT values were significantly different between JT and U (p = 0.010). Conclusions : mtDNA haplogroups showed different response to ranibizumab at 12 month. It could be a potencial biomarker to predict the response to this therapy in nAMD patients. info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 3.47 2019 OPHTHALMOLOGY 10 / 60 = 0.167 2019 Q1 T1 1.789 2019 Ophthalmology 2019 Q1 Sensory Systems 2019 Q1 Cellular and Molecular Neuroscience 2019 Q2 info:eu-repo/semantics/conferenceObject info:eu-repo/semantics/publishedVersion Esteban, O. Montoya, J. Universidad de Zaragoza (orcid)0000-0003-1770-6299 Montes, P. Mateo, J. Lara, J. Ruiz-Pesini, E. Universidad de Zaragoza (orcid)0000-0002-0269-7337 1004 646 Universidad de Zaragoza Dpto. Cirugía,Ginecol.Obstetr. Área Oftalmología 1002 060 Universidad de Zaragoza Dpto. Bioq.Biolog.Mol. Celular Área Bioquímica y Biolog.Mole. 60, 9 (2019), [3 pp] Investig. ophthalmol. vis. sci. Investigative ophthalmology & visual science 0146-0404 490633 http://zaguan.unizar.es/record/98412/files/texto_completo.pdf Versión publicada 1861811 http://zaguan.unizar.es/record/98412/files/texto_completo.jpg?subformat=icon icon Versión publicada https://iovs.arvojournals.org/article.aspx?articleid=2746228 Texto completo de la revista oai:zaguan.unizar.es:98412 articulos driver 2021-12-16-13:05:24 ARTICLE